The acquisition of Cardiogenesis
adds to the company's portfolio a leading surgical product used in the treatment of diffuse coronary artery disease and severe angina.
In a related but separate matter, CardioGenesis
was served, at its California offices, on Friday, September 12, 1997 with a complaint filed by PLC in Munich, Germany alleging that both CardioGenesis
and its former German sales agent have infringed EP 553 576, a European counterpart of the '926 patent.
The investigation concerns whether the Cardiogenesis
Board of Directors breached their fiduciary duties to Cardiogenesis
stockholders by failing to adequately shop the Company before entering into this transaction and whether CryoLife, Inc.
Of those shares tendered, 23,221,166 shares of Cardiogenesis
common stock, representing approximately 49.
is advancing the TMR therapy with innovative new tools building on the foundation of their flexible fiberoptic delivery system, enabling delivery through small ports in a closed-chest, robotically assisted technique.
In addition, we completed our preclinical work at the Texas Heart Stem Cell Center which included bone marrow compatibility testing as well as a large animal safety study for the PHOENIX(TM) System," said Cardiogenesis
Executive Chairman Paul McCormick.
A more detailed description of the Cardiogenesis
Board of Directors' recommendation regarding the merger can be found in the Solicitation/Recommendation Statement on Schedule 14D-9 prepared by Cardiogenesis
, which was mailed to Cardiogenesis
stockholders and which was filed with the Securities and Exchange Commission (SEC) on April 5, 2011.
Based on the PMC's success to date in treating severe chronic angina in Europe, where Cardiogenesis
currently has CE Mark approval, we expect that, when approved for use in the U.
2 million related to the Company's proposed acquisition of Cardiogenesis
and other business development activities, non-GAAP adjusted net income for the first quarter of 2011 was $2.
April 20, 2011 /PRNewswire/ -- Cardiogenesis
Corporation (OTCQB: CGCP) announced that the company will release results for its first quarter ended March 31, 2011 on Wednesday, May 4, 2011.
, Strauss served as director of finance for South San Francisco-based Telik Inc.
NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, today announced the expiration of the 20-day "go-shop" period that is part of its definitive agreement with Cardiogenesis
"), whereby CryoLife is conducting a cash tender offer for 49.